JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB130042

Recombinant Human SBCAD protein (His tag N-Terminus)

Be the first to review this product! Submit a review

|

(0 Publication)

Recombinant Human SBCAD protein (His tag N-Terminus) is a Human Full Length protein, in the 34 to 432 aa range, expressed in Escherichia coli, with >90%, suitable for SDS-PAGE.

View Alternative Names

SBCAD, 2-methyl branched chain acyl-CoA dehydrogenase, 2-methylbutyryl-coenzyme A dehydrogenase, 2-MEBCAD, 2-methylbutyryl-CoA dehydrogenase, ACADSB

1 Images
SDS-PAGE - Recombinant Human SBCAD protein (His tag N-Terminus) (AB130042)
  • SDS-PAGE

Unknown

SDS-PAGE - Recombinant Human SBCAD protein (His tag N-Terminus) (AB130042)

15% SDS-PAGE showing ab130042 (3 µg).

Key facts

Purity

>90% SDS-PAGE

Expression system

Escherichia coli

Tags

His tag N-Terminus

Applications

SDS-PAGE

applications

Biologically active

No

Accession

P45954

Animal free

No

Carrier free

No

Species

Human

Storage buffer

pH: 8 Constituents: 10% Glycerol (glycerin, glycerine), 0.58% Sodium chloride, 0.32% Tris HCl, 0.02% (R*,R*)-1,4-Dimercaptobutan-2,3-diol

storage-buffer

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "SDS-PAGE": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }
style
left-column

Product details

Previously labelled as ACADSB.
style
left-column

Sequence info

[{"sequence":"MGSSHHHHHHSSGLVPRGSHMGSHMKSSQSEALLNITNNGIHFAPLQTFTDEEMMIKSSVKKFAQEQIAPLVSTMDENSKMEKSVIQGLFQQGLMGIEVDPEYGGTGASFLSTVLVIEELAKVDASVAVFCEIQNTLINTLIRKHGTEEQKATYLPQLTTEKVGSFCLSEAGAGSDSFALKTRADKEGDYYVLNGSKMWISSAEHAGLFLVMANVDPTIGYKGITSFLVDRDTPGLHIGKPENKLGLRASSTCPLTFENVKVPEANILGQIGHGYKYAIGSLNEGRIGIAAQMLGLAQGCFDYTIPYIKERIQFGKRLFDFQGLQHQVAHVATQLEAARLLTYNAARLLEAGKPFIKEASMAKYYASEIAGQTTSKCIEWMGGVGYTKDYPVEKYFRDAKIGTIYEGASNIQLNTIAKHIDAEY","proteinLength":"Full Length","predictedMolecularWeight":"46.4 kDa","actualMolecularWeight":null,"aminoAcidEnd":432,"aminoAcidStart":34,"nature":"Recombinant","expressionSystem":"Escherichia coli","accessionNumber":"P45954","tags":[{"tag":"His","terminus":"N-Terminus"}]}]
style
left-column

Properties and storage information

Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
False
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

SBCAD also known as short/branched-chain acyl-CoA dehydrogenase is an enzyme involved in the mitochondrial fatty acid beta-oxidation pathway. It has a molecular mass of approximately 42 kDa. The enzyme functions to catalyze the initial step of the beta-oxidation process specifically targeting short and branched-chain acyl-CoA substrates. SBCAD shows widespread expression notably in tissues with high fatty acid metabolism such as the liver heart and skeletal muscle.
Biological function summary

This enzyme plays a critical role in energy production by facilitating the breakdown of fatty acids to produce acetyl-CoA which subsequently enters the citric acid cycle for ATP generation. SBCAD is not a part of a larger enzyme complex but works in conjunction with other enzymes in the beta-oxidation pathway. Its function is essential for maintaining energy homeostasis particularly during periods when carbohydrates may be less available and the body relies on stored fats.

Pathways

The main involvement of SBCAD is in the fatty acid degradation and energy metabolism pathways. It is closely related to other acyl-CoA dehydrogenases such as medium-chain acyl-CoA dehydrogenase (MCAD) and very-long-chain acyl-CoA dehydrogenase (VLCAD) which also participate in the stepwise oxidation of different acyl-CoA derivatives. Together these enzymes ensure efficient fatty acid breakdown and energy release through the coordinated action of the beta-oxidation cycle leading into the citric acid cycle.

Mutations in the SBCAD gene can lead to short/branched-chain acyl-CoA dehydrogenase deficiency a metabolic disorder characterized by an inability to properly break down certain types of fatty acids. This condition can result in various symptoms including muscle weakness hypoglycemia and metabolic crises often aggravated by fasting or illness. SBCAD's function interlinks with other metabolic enzymes where its deficiency might show overlapping symptoms with disorders involving MCAD and other related enzymes in the beta-oxidation sequence. Understanding SBCAD’s role is important in diagnosing and managing metabolic conditions linked to fatty acid oxidation defects.
style
left-column

Specifications

Form

Liquid

Additional notes

ab130042 is purified using conventional chromatography techniques.

style
left-column

General info

Function

Short and branched chain specific acyl-CoA dehydrogenase that catalyzes the removal of one hydrogen from C-2 and C-3 of the fatty acyl-CoA thioester, resulting in the formation of trans-2-enoyl-CoA (PubMed : 10832746, PubMed : 11013134, PubMed : 21430231, PubMed : 7698750). Among the different mitochondrial acyl-CoA dehydrogenases, acts specifically on short and branched chain acyl-CoA derivatives such as (S)-2-methylbutyryl-CoA as well as short straight chain acyl-CoAs such as butyryl-CoA (PubMed : 10832746, PubMed : 11013134, PubMed : 21430231, PubMed : 7698750). Plays an important role in the metabolism of L-isoleucine by catalyzing the dehydrogenation of 2-methylbutyryl-CoA, one of the steps of the L-isoleucine catabolic pathway (PubMed : 10832746, PubMed : 11013134). Can also act on valproyl-CoA, a metabolite of valproic acid, an antiepileptic drug (PubMed : 8660691).

Sequence similarities

Belongs to the acyl-CoA dehydrogenase family.

Subcellular localisation

Mitochondrion matrix

style
left-column

Product protocols

style
left-column

Target data

Short and branched chain specific acyl-CoA dehydrogenase that catalyzes the removal of one hydrogen from C-2 and C-3 of the fatty acyl-CoA thioester, resulting in the formation of trans-2-enoyl-CoA (PubMed : 10832746, PubMed : 11013134, PubMed : 21430231, PubMed : 7698750). Among the different mitochondrial acyl-CoA dehydrogenases, acts specifically on short and branched chain acyl-CoA derivatives such as (S)-2-methylbutyryl-CoA as well as short straight chain acyl-CoAs such as butyryl-CoA (PubMed : 10832746, PubMed : 11013134, PubMed : 21430231, PubMed : 7698750). Plays an important role in the metabolism of L-isoleucine by catalyzing the dehydrogenation of 2-methylbutyryl-CoA, one of the steps of the L-isoleucine catabolic pathway (PubMed : 10832746, PubMed : 11013134). Can also act on valproyl-CoA, a metabolite of valproic acid, an antiepileptic drug (PubMed : 8660691).
See full target information Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial
style
left-column
style
left-column
style
right-column

Complementary Products

Primary Antibodies

AB99951

Anti-SBCAD antibody

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-SBCAD antibody (AB99951)

  • 0
  • 0
Proteins & Peptides

AB104900

Recombinant Human BCKDHA protein (His tag N-Terminus)

SDS-PAGE - Recombinant Human BCKDHA protein (His tag N-Terminus) (AB104900)

  • 0
  • 0
Primary Antibodies

AB58988

Anti-Prolyl Endopeptidase antibody

Western blot - Anti-Prolyl Endopeptidase antibody (AB58988)

  • 4
  • 1
Primary Antibodies

AB118797

Anti-CEP128 antibody

Immunoprecipitation - Anti-CEP128 antibody (AB118797)

  • 5
  • 1

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com